Navigation Links
Medarex Announces 2007 Fourth Quarter and Year End Financial Results
Date:2/26/2008

ct development and business activities during the fourth quarter of 2007 include the following:

-- Announcing the receipt of a milestone payment from our licensing

partner, Centocor, Inc., in connection with Centocor's submission of

regulatory applications requesting approval of ustekinumab (CNTO 1275),

an anti-IL-12/IL-23 human antibody for the treatment of chronic

moderate to severe plaque psoriasis that was generated using Medarex's

UltiMAb(R) technology;

-- Announcing top-line data from the three registrational trials

evaluating ipilimumab as a monotherapy for the treatment of second-line

(previously treated) metastatic melanoma, with a goal to file a

Biologics License Application (BLA) in the first-half of 2008;

-- Filing an investigational new drug (IND) application with the U.S. Food

and Drug Administration (FDA) for MDX-1411, a fully human anti-CD70

antibody in development for the treatment of clear cell renal cancer;

-- Filing two separate INDs with the FDA for MDX-1342, a fully human anti-

CD19 antibody in development for the treatment of chronic lymphocytic

leukemia and for rheumatoid arthritis;

-- Filing an IND with the FDA for MDX-1106, a fully human anti-PD-1

antibody in development with Ono Pharmaceutical Co., Ltd, being

investigated for the treatment of chronic viral infections, with the

first trial to target hepatitis C; and

-- Receiving a milestone payment from Amgen, Inc., for the advancement of

Amgen's fifth UltiMAb(R)-derived antibody into clinical development.

In addition to fourth quarter events, other activities in 2007 include:

-- Presenting encouraging Phase 2 and Phase 1 clinical data from multiple

ipilimumab trials for the treatment of metastatic melanoma and prostate

cancer at the annual meeting of the American Society o
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
2. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
3. PharmAthene and Medarex Announce Additional $0.8 Million U.S. Government Appropriation for Continued Development of Anthrax Therapeutic Valortim(TM)
4. Medarex to Present at the JPMorgan Small/Mid Cap Conference
5. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
6. Grupo Casa Saba Announces Fourth Quarter 2007 Results
7. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
8. Reproductive Medicine Associates of Texas Announces Open House in San Antonio
9. WallSt.net (www.WallSt.net) Announces Upcoming Interview With Chairman and CEO of flexSCAN, Inc.
10. Hospira Announces New Contract With HealthTrust Purchasing Group for Infusion Devices, Solutions and Equipment
11. Thomson Healthcare Announces Enhancements to Order Sets Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Angeldress.co.uk, a renowned wedding dress ... ladies to obtain their dream garments at affordable prices. ... special occasion outfits for clients from all over the ... latest designs and the information on how to choose ... Recently, the company has unveiled its new collection of ...
(Date:7/24/2014)... Discount-Dress.com, an innovative company that provides ... outfits, is doing its best to attract new clients. ... rates, up to 75% off. Recently, the company has ... Also, it has unveiled many new products for ladies ... lace wedding dresses, purple prom dresses and so forth. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 A study ... Pediatrics was conducted by Dr. Shonna Yin of NYU’s Langone ... poison centers each year are due to confusion over liquid ... recommended dosage amounts for adults versus children, Yin warns it ... , When tested, roughly 40 percent of parents in the ...
(Date:7/24/2014)... July 24, 2014 American Sentinel ... Identify and Prevent the Three Infections That Make ... is a go-to guide to help nurses minimize ... and details basic prevention measures that every nurse ... is available for download at http://www.americansentinel.edu/blog/2014/05/13/strong-nursing-leadership-is-essential-to-reducing-hais/ . ...
(Date:7/24/2014)... Crawford Technologies today announced the results ... AIIM, focusing on global trends in high-volume transactions ... survey indicated that even though organizations stated the ... service, legal and regulatory compliance and historical record ... facsimiles of these documents. , The survey found ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk, A Renowned Wedding Dress Manufacturer And Retailer, Vows To Offer The Best Bridesmaid Dresses For Ladies 2Health News:Discount-Dress.com Announces the Launch of Its New Blog and Publishes Articles About Its Fabulous Special Occasion Dresses 2Health News:Many Parents Confused by Over-The-Counter Medications and OTCPlus App Solves This Problem 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 2Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 3Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 4
... rates in South, Southwest; lowest rates in Northeast, government reports ... rate in the United States increased in 26 of the ... country, according to a new government report. , Back ... Prevention reported that the teen birth rate for the entire ...
... recognized inpatient treatment center, is pleased to announce its plans ... is just a few of the ways Seabrook ... possible and that treatment works. Seabrook House,s vision is to ... to educate the public at large in an effort to ...
... Top Government Officials Will Explain Regulatory Plans for Cutting-Edge Technology ... , DC . WASHINGTON, Jan. 7 ... goods last year. By 2014, the market will grow to ... and therapeutics will be sold--up from more than $3 billion ...
... more and more Michigan residents,losing employer-sponsored health coverage, the ... To ease the burden, the Blue Cross,Blue Shield ... in matching,funds for projects that improve health care access ... "Fundable projects for the uninsured include creative and novel ...
... teenage boys don,t seem to be as susceptible, study suggests ... spend more than two hours of "screen time" a day ... to be physically fit, a new Australian study finds. , ... more likely to be able to "sit and be fit," ...
... COLUMBIA, Mo. There is no cure for spinal ... weakening of muscles and is the leading genetic cause ... discovered a new therapeutic target that improves deteriorating skeletal ... muscle strength, improved gross motor skills and increased the ...
Cached Medicine News:Health News:Teen Birth Rate Up in 26 States in 2006 2Health News:Seabrook House Embraces the New Year with New Programs 2Health News:Seabrook House Embraces the New Year with New Programs 3Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 2Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 3Health News:Food and Drug Law Institute Sponsors Major Conference on Nanotechnology Law, Regulation and Policy 4Health News:$1 Million Available to Help Michigan's Uninsured Receive Care 2Health News:More 'Screen Time' Linked to Poor Fitness in Girls 2Health News:Researchers discover target that could ease spinal muscular atrophy symptoms 2
(Date:7/24/2014)... DALLAS , July 24, 2014  Market ... of IVD Insights™ LabFile , a data ... the US clinical laboratory universe and identifying target ... is a proprietary database that provides IVD manufacturers ... clinical tests, relying on clear and consistent definitions ...
(Date:7/24/2014)... 24, 2014 HIGHLIGHTS:Q2 2014 Results (all ... , Reported sales increased 3% to $701 million.  Sales grew ... added one percentage point to sales growth. , By ... in Applied and 1% in SAFC Commercial. , Reported ... an increase of 13%.  Adjusted diluted EPS in Q2 2014 ...
(Date:7/24/2014)... DIEGO , July 24, 2014   ... announced today a co-promotion agreement with Illumina to ... genome sequence data for precision medicine and clinical ... pharmaceutical companies, through Illumina,s sales force, a solution ... platform for data analytics and storage, and Cypher ...
Breaking Medicine Technology:MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 16Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 17Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 18Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 19Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 20Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 21Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 22Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 2Cypher Genomics and Illumina Enter Agreement to Facilitate Genomic Biomarker Discovery 3
... Alpharma Inc.,(NYSE: ALO ), a ... its Phase III pivotal efficacy trial that ... naltrexone,hydrochloride) capsules provided significant pain relief in ... osteoarthritis of the hip or knee compared,to ...
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... mitogen-activated ERK kinase (MEK) inhibitor, RDEA119,at the American College ... & Convention Center in Orlando., ... October 7, 2008 from 10:30 a.m. - 4:00 p.m. ...
Cached Medicine Technology:Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 2Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 3Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 4Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting 5Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting 2
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: